COMPASS Pathways (CMPS) KOL Event summary

Introduction and agenda

• Provided updates on COMP360 programs for PTSD and TRD, including pivotal trial designs, commercial readiness, and completion of enrollment in the second phase III TRD trial.

• Hosted webinars and roundtables with KOLs and industry leaders to discuss integration of COMP360 into clinical practice and commercial launch readiness.

• FDA accepted the IND application for COMP360 in PTSD, enabling a late-stage clinical trial launch.

• The event focused on unmet needs and current treatment landscapes for PTSD and TRD, clinical data for COMP360, and included fireside chats and Q&A.

KOL background and credentials

• Featured Dr. Gary Small (Hackensack Meridian Health), Dr. Geoffrey Grammer (Greenbrook), Myriam Barthes (Journey Clinical), and Dimitri Cavathas (HealthPort), all with significant interventional psychiatry experience.

• Presenters included company executives and external experts from academic and clinical backgrounds.

Market insights and analysis

• PTSD affects over 13 million adults in the US annually, with high economic and societal burden and only two FDA-approved medications.

• TRD impacts about 4 million US adults, with limited effective options, high costs, and only two approved medicines.

• TRD patients experience longer depressive episodes, higher mortality, and greater work loss compared to MDD.

• Interventional psychiatry infrastructure is rapidly expanding, with over 6,800 centers in the US and evolving treatment models.

• Spravato is the only widely used TRD drug, but is operationally burdensome and limits patient access.